Effect of Remazolam combined with Esketamine on extubation choking response and postoperative recovery in patients undergoing thyroid surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090449

Enrollment

Unknown

Registered

2024-09-30

Start date

2023-03-21

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroidectomy surgery

Interventions

Group C:normal saline

Group S1:Esketamine loading dose:0.15mg/kg

maintenance dose:0.15mg/kg/h

Group S2:Esketamine loading dose:0.25mg/kg

maintenance dose:0.25mg/kg/h

Group S3 :Esketamine loading dose:0.35mg/kg IV

maintenance dose:0.35mg/kg/h

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-65 years old, gender is not limited; (2) ASA grade I ~ II; (3) Those with good nutritional status; (4) No serious circulatory, respiratory, nervous and other systemic diseases;

Exclusion criteria

Exclusion criteria: (1) Combined with other serious congenital systemic diseases (such as heart and lung diseases); (2) Those with cognitive dysfunction or fine diseases; (3) Those who have taken sedative, analgesic or sleeping drugs for a long time in the past (4) Huge thyroid mass (> 5.0 cm), hyperthyroidism; (5) Patients with choking due to primary disease before surgery;

Design outcomes

Primary

Measure	Time frame
Minogue;NRS;	—

Secondary

Measure	Time frame
Hemodynamic changes;Extubation time;HADS;QoR15;Adverse reactions;	—

Countries

China

Contacts

Public ContactFang Hua

Guizhou Provincial People's Hospital

succiniter@126.com+86 186 8519 3576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026